Home > Healthcare > Pharmaceuticals > Finished Drug Form > Morphine Drugs Market

Morphine Drugs Market Share

Report ID: GMI9319
Published Date: May 2024
Report Format: PDF

Download Free Sample

Morphine Drugs Market Share

The morphine drugs industry commands a significant position in pharmaceuticals, driven by the global burden of chronic pain and increasing cancer cases. Morphine, renowned for its potent pain-relieving properties, is pivotal in managing moderate to severe pain across diverse medical domains, including oncology, surgery, and palliative care. Offering various formulations like injectables, oral tablets, and transdermal patches, the market caters to diverse patient preferences. Stringent regulations, technological advancements, and evolving healthcare infrastructures globally further shape the competitive landscape, indicating steady growth prospects as healthcare prioritizes pain management and palliative care services.

Morphine Drugs Market Companies

Prominent players operating in the morphine drugs industry include:

Alcaliber S.A.
Daiichi Sankyo Company Limited
Hikma Pharmaceuticals PLC
Mallinckrodt plc
Pfizer Inc.
Purdue Pharma L.P.
Sandoz AG
Taj Pharmaceuticals Limited
Verve Health Care Ltd.
Viatris Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of morphine drugs reached USD 23.4 billion in 2023 and is set to witness 6.5% CAGR from 2024 to 2032, attributed to the ongoing advancements in drug delivery systems, increasing prevalence of chronic pain and rising geriatric population.

The injectable segment generated USD 16.9 billion in 2023, owing to the increasing number of surgical procedures worldwide.

North America market accounted for USD 8.6 billion in 2023 and is anticipated to grow at 6.2% CAGR between 2024 and 2032, driven by the chronic pain conditions, such as arthritis, back pain, and neuropathic pain.

Alcaliber S.A., Daiichi Sankyo Company Limited, Hikma Pharmaceuticals PLC, Mallinckrodt plc, Pfizer Inc., Purdue Pharma L.P., Sandoz AG, Taj Pharmaceuticals Limited, Verve Health Care Ltd. and Viatris Inc.